UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): July 9, 2007
 
Manhattan Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-32639
 
36-3898269
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
810 Seventh Avenue, 4th Floor
New York, New York 10019
(Address of principal executive offices) (Zip Code)

(212) 582-3950
(Registrant's telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

Item 8.01 Other Events
 
Manhattan Pharmaceuticals, Inc.’s (the “Company”) press release dated July 9, 2007, which announced the results of the Company’s Phase 2a studies for Oral Oleoyl-estrone and information on accessing a management discussion teleconference to be held at 8:30am ET on Tuesday, July 10, 2007, is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d)
Exhibits.

Exhibit No.
 
Description
99.1
 
Manhattan Pharmaceuticals, Inc. press release dated July 9, 2007.
 
 
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
MANHATTAN PHARMACEUTICALS, INC.
 
 
 
 
 
 
Date: July 9, 2007
By:  
/s/ Michael G. McGuinness
 
Michael G. McGuinness
 
Chief Financial Officer
 
 
 
 
 
EXHIBIT INDEX

Exhibit No.
Description
99.1
 
Manhattan Pharmaceuticals, Inc. press release dated July 9, 2007.